278 related articles for article (PubMed ID: 19855393)
21. Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi.
Hafner C; van Oers JM; Vogt T; Landthaler M; Stoehr R; Blaszyk H; Hofstaedter F; Zwarthoff EC; Hartmann A
J Clin Invest; 2006 Aug; 116(8):2201-2207. PubMed ID: 16841094
[TBL] [Abstract][Full Text] [Related]
22. Molecular investigation of FGFR3 gene mutation and its correlation with clinicopathological findings in Indian bladder cancer patients.
Ahmad F; Mahal V; Verma G; Bhatia S; Das BR
Cancer Rep (Hoboken); 2018 Oct; 1(3):e1130. PubMed ID: 32721083
[TBL] [Abstract][Full Text] [Related]
23. A novel somatic FGFR3 mutation in primary lung cancer.
Shinmura K; Kato H; Matsuura S; Inoue Y; Igarashi H; Nagura K; Nakamura S; Maruyama K; Tajima M; Funai K; Ogawa H; Tanahashi M; Niwa H; Sugimura H
Oncol Rep; 2014 Mar; 31(3):1219-24. PubMed ID: 24452392
[TBL] [Abstract][Full Text] [Related]
24. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.
Zieger K; Dyrskjøt L; Wiuf C; Jensen JL; Andersen CL; Jensen KM; Ørntoft TF
Clin Cancer Res; 2005 Nov; 11(21):7709-19. PubMed ID: 16278391
[TBL] [Abstract][Full Text] [Related]
25. No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer.
Otto W; Denzinger S; Bertz S; Gaumann A; Wild PJ; Hartmann A; Stoehr R
Int J Cancer; 2009 Nov; 125(9):2205-8. PubMed ID: 19621447
[TBL] [Abstract][Full Text] [Related]
26. The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas.
Kimura T; Suzuki H; Ohashi T; Asano K; Kiyota H; Eto Y
Cancer; 2001 Nov; 92(10):2555-61. PubMed ID: 11745189
[TBL] [Abstract][Full Text] [Related]
27. Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation.
Rosty C; Aubriot MH; Cappellen D; Bourdin J; Cartier I; Thiery JP; Sastre-Garau X; Radvanyi F
Mol Cancer; 2005 May; 4(1):15. PubMed ID: 15869706
[TBL] [Abstract][Full Text] [Related]
28. FGFR3 mutations in seborrheic keratoses are already present in flat lesions and associated with age and localization.
Hafner C; Hartmann A; van Oers JM; Stoehr R; Zwarthoff EC; Hofstaedter F; Landthaler M; Vogt T
Mod Pathol; 2007 Aug; 20(8):895-903. PubMed ID: 17585316
[TBL] [Abstract][Full Text] [Related]
29. Oncogenic Activation of Fibroblast Growth Factor Receptor-3 and RAS Genes as Non-Overlapping Mutual Exclusive Events in Urinary Bladder Cancer.
Pandith AA; Hussain A; Khan MS; Shah ZA; Wani MS; Siddiqi MA
Asian Pac J Cancer Prev; 2016; 17(6):2787-93. PubMed ID: 27356691
[TBL] [Abstract][Full Text] [Related]
30. FGFR3, PIK3CA and RAS mutations in benign lichenoid keratosis.
Groesser L; Herschberger E; Landthaler M; Hafner C
Br J Dermatol; 2012 Apr; 166(4):784-8. PubMed ID: 22188534
[TBL] [Abstract][Full Text] [Related]
31. Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events.
Serizawa RR; Ralfkiaer U; Steven K; Lam GW; Schmiedel S; Schüz J; Hansen AB; Horn T; Guldberg P
Int J Cancer; 2011 Jul; 129(1):78-87. PubMed ID: 20824703
[TBL] [Abstract][Full Text] [Related]
32. No evidence of FGFR3 mutations in prostate cancer.
Zuiverloon TC; Boormans JL; Trapman J; van Leenders GJ; Zwarthoff EC
Prostate; 2011 May; 71(6):637-41. PubMed ID: 20957671
[TBL] [Abstract][Full Text] [Related]
33. Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.
Foldynova-Trantirkova S; Wilcox WR; Krejci P
Hum Mutat; 2012 Jan; 33(1):29-41. PubMed ID: 22045636
[TBL] [Abstract][Full Text] [Related]
34. Detection of RAS mutations in archival testicular germ cell tumors by polymerase chain reaction and oligonucleotide hybridization.
Moul JW; Theune SM; Chang EH
Genes Chromosomes Cancer; 1992 Sep; 5(2):109-18. PubMed ID: 1381946
[TBL] [Abstract][Full Text] [Related]
35. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.
Jebar AH; Hurst CD; Tomlinson DC; Johnston C; Taylor CF; Knowles MA
Oncogene; 2005 Aug; 24(33):5218-25. PubMed ID: 15897885
[TBL] [Abstract][Full Text] [Related]
36. FGFR3 mutations in benign skin tumors.
Hafner C; Vogt T; Hartmann A
Cell Cycle; 2006 Dec; 5(23):2723-8. PubMed ID: 17172848
[TBL] [Abstract][Full Text] [Related]
37. Mutational activation of FGFR3: no involvement in the development of renal cell carcinoma.
Stoehr CG; Stoehr R; Hartmann A; Hofstaedter F; Junker K; Blaszyk H; Wieland WF; Otto W; Denzinger S; Walter B
J Cancer Res Clin Oncol; 2012 Feb; 138(2):359-61. PubMed ID: 22203473
[TBL] [Abstract][Full Text] [Related]
38. FGFR3 and TP53 mutations in a prospective cohort of Belarusian bladder cancer patients.
Smal MP; Rolevich AI; Polyakov SL; Krasny SA; Goncharova RI
Exp Oncol; 2014 Dec; 36(4):246-51. PubMed ID: 25537218
[TBL] [Abstract][Full Text] [Related]
39. Disruption of a Sox9-β-catenin circuit by mutant Fgfr3 in thanatophoric dysplasia type II.
Shung CY; Ota S; Zhou ZQ; Keene DR; Hurlin PJ
Hum Mol Genet; 2012 Nov; 21(21):4628-44. PubMed ID: 22843502
[TBL] [Abstract][Full Text] [Related]
40. Rapid detection of K650E mutation in FGFR3 using uncultured amniocytes in a pregnancy affected with fetal cloverleaf skull, occipital pseudoencephalocele, ventriculomegaly, straight short femurs, and thanatophoric dysplasia type II.
Chen CP; Chang TY; Lin MH; Chern SR; Su JW; Wang W
Taiwan J Obstet Gynecol; 2013 Sep; 52(3):420-5. PubMed ID: 24075385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
